Open Medical and Digital Diagnostics Sign MoU to Collaborate on Deploying Fully-Autonomous AI-Powered Diabetic Eye Screening, Integrated With Advanced Clinical Workflows, Across the GCC
© Open Medical 2025. All Rights Reserved
LONDON – August 20, 2025 - Open Medical, a leading UK-based digital healthcare company, and Digital Diagnostics, the US-based creator of the first FDA-cleared fully autonomous AI system for the diagnosis of diabetic retinopathy, today signed an Memorandum of Understanding to partner on combating diabetic-related vision loss across the Gulf Cooperation Council (GCC) region and enhancing integrated healthcare delivery.
The collaboration will integrate Digital Diagnostics' groundbreaking AI system, LumineticsCore™, into Open Medical's clinical workflow platform, Ensiab. This will enable healthcare providers in the region to perform on-site diagnostic testing for diabetic retinopathy at the point of care, dramatically increasing access to critical screening for the millions of people living with diabetes in the GCC.
The partnership comes at a pivotal time as the GCC region undergoes rapid technological evolution in healthcare, with significant investments in digital transformation and AI-powered solutions. The Memorandum of Understanding (MOU) between Open Medical and Digital Diagnostics establishes a framework for collaborative efforts in medical services, medical technology, and digital health. This initiative supports the broader goal of a systematic shift toward value-based, AI-first healthcare, with both public and private sectors working together to deploy scalable, patient-centered technologies.
"The prevalence of diabetes in the GCC region necessitates robust and accessible screening programs.” said Ayman Ababneh, General Manager of Open Medical in Saudi Arabia. “Our collaboration with Digital Diagnostics allows us to integrate their cutting-edge AI-powered diagnostic solutions with our digital health platforms, revolutionizing diabetic care and vastly improving early detection capabilities. This synergy will lead to more personalized patient outcomes and significantly reduce healthcare costs by preventing complications. We are poised to deliver a more connected and efficient healthcare experience for the population, aligning with the ambitious digital health transformation vision of the GCC."
Through this agreement, Open Medical and Digital Diagnostics are committed to spearheading the digital health revolution in the GCC, contributing to a healthier and more prosperous future for the region's population.
About Open Medical
Open Medical is a UK-based digital healthcare company delivering award-winning, cloud-based software for clinical and operational pathway management. Powered by its Ensiab platform, Open Medical’s solutions improve care coordination, patient outcomes, and healthcare system efficiency. Over 200 healthcare sites across the UK, Europe, and the Middle East use Ensiab to deliver efficient patient care and optimize healthcare delivery.
About Digital Diagnostics
Digital Diagnostics is a pioneering healthcare technology company that designs and deploys autonomous AI systems for diagnosing disease from high-quality images. Its flagship product, LumineticsCore™ (formerly IDx-DR), is the first-ever FDA-cleared, fully autonomous AI system for the diagnosis of diabetic retinopathy. Digital Diagnostics’ mission is to benefit patients by developing technology to make healthcare easier to access, affordable, available to everyone, and of the highest quality.
